Skip to content
  • Contact Us Today
Seven and Eight Biopharmaceuticals Inc
  • Home
  • About Us
    • Company Overview
    • Leadership Team
    • Partners
    • Contact Us
  • News
    • Events & Presentations
    • In the Press
  • Pipeline & Research
    • Overview
  • Careers
Events & Presentations

Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

  • June 7, 2021
  • Julie Ha

  Abstract Title: BDB001, an intravenously administered toll-like receptor 7 and 8 (TLR7/8) agonist, in combination with pembrolizumab in advanced solid tumors: Phase 1 safety and efficacy results.  Abstract Authors: Manish R. Patel, Anthony W. Tolcher, Drew W. Rasco, Melissa Lynne Johnson, Angela Tatiana Alistar, Lixin Li, Alexander H. Chung, Robert H.I. Andtbacka  Session Title: Poster Discussion […]

Read More

Seven and Eight Biopharma to present at the STING & TLR-Targeting Therapies Summit

  • May 25, 2021
  • Julie Ha

Robert Andtbacka, M.D., C.M., Chief Medical Officer, will give a presentation “BDB001, an Intravenously Delivered TLR7/8 Dual Agonist in Advanced Solid Tumors” during The 2nd STING- & TLR-Targeting Therapies Summit, on May 26, 2021. This presentation will highlight the TLR7/8 dual agonist program at Seven and Eight Biopharma and the recent clinical advances. The conference […]

Read More

Presents Promising Interim Phase 1 Results

  • November 17, 2020
  • wpengine

Seven and Eight Biopharma Presents Promising Interim Phase 1 Results for BDB001 at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting SITC 2020 Poster Nov 09, 2020 at 08:00 AM EST EDISON, N.J., Nov. 09, 2020 – Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel […]

Read More
Recent Posts
  • Seven and Eight Biopharma’s BDB001 in Combination with an anti-PD-L1 mAb Shows Favorable Safety and Clinical Responses in Interim Phase 1 Data Presented at the 2021 SITC Annual Meeting
  • Seven and Eight Biopharmaceuticals Inc. Announces the First Patient Treated in a Phase 2 Clinical Trial of the TLR 7/8 dual agonist BDB001 in anti-PD-1 / anti-PD-L1 Refractory Solid Tumors
  • Seven and Eight Biopharmaceuticals Inc. Announces the First Patient Treated in a First-in-Human Clinical Trial of the TLR7/8 dual agonist BDB018 in Advanced Solid Tumors
  • Seven and Eight Biopharma’s BDB001 in Combination with Pembrolizumab Shows Favorable Safety and Clinical Responses in Interim Phase 1 Data Presented at the 2021 ASCO Annual Meeting
  • Institut Bergonié and Seven and Eight Biopharmaceuticals Inc. Announce the First Patient Treated in the AGADIR Study of BDB001 in Combination with Atezolizumab and Immunogenic Radiotherapy in Solid Tumors
Recent Comments
    Archives
    • November 2021
    • September 2021
    • June 2021
    • May 2021
    • April 2021
    • November 2020
    • December 2019
    • June 2019
    Categories
    • Collaborations
    • Events
    Meta
    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • ©Seven and Eight Biopharmaceuticals Inc. All rights reserved. |
    • Sitemap